Portage Biotech Inc Company Overview
Portage Biotech Inc
About Portage Biotech Inc
Portage Biotech (NASDAQ:PRTG) is deeply involved in developing a diverse portfolio of immuno-oncology therapies aimed at treating a range of cancers. Traded on the NASDAQ stock exchange under the ticker code PRTG, the company is committed to advancing therapies that harness the body's immune system to combat cancer. Portage focuses on innovative projects that include both early-stage research and clinical development of targeted treatments. The company's main objective is synthesizing novel drug candidates and advancing them through clinical trials to address unmet medical needs in oncology. Through strategic collaborations, Portage aims to expand its capabilities and accelerate the commercialization of its therapeutic candidates.
What is Portage Biotech Inc known for?
Snapshot
-
Year founded
3
Employees
Toronto, Canada
Head office
Loading Map...
Operations
All Locations
Canada
Produtos e/ou serviços de Portage Biotech Inc
- Developing innovative immuno-oncology therapies focused on novel mechanisms to enhance the immune system's ability to detect and destroy cancer cells.
- Advancing clinical trials for broad-spectrum checkpoint inhibitors designed to overcome immune suppression and enhance cancer treatment efficacy across various tumor types.
- Exploring tumor-targeting adjuvants that augment the effectiveness of existing immunotherapy treatments by activating immune cells at the tumor site for improved outcomes.
- Leveraging cutting-edge nanoparticle technology aimed at delivering unique, more potent cancer therapies directly to the tumor, minimizing systemic side effects.
- Investing in strategic partnerships and collaborations to expand the reach and accelerate the development of their immunotherapy drug candidates.
- Implementing a robust research and development pipeline, prioritizing diverse therapeutic candidates with the potential to disrupt traditional cancer treatment paradigms.
equipe executiva do Portage Biotech Inc
- Adam MeleroController
- Mr. Peter MolloyChief Executive Officer of Cyncado Therapeutics Inc.